Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine ("Insilico") has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.

16 Oct 2023

Engineered bacteria deliver synthetic targets to solid tumors

For several years, researchers have been successfully using chimeric antigen receptor (CAR) T cells to target specific antigens found on blood cells as a cure for patients with leukemia and lymphoma.

12 Oct 2023

Study finds increased risk of birth defects for offspring of young women with cancer

The offspring of adolescent and young adult women with a history of cancer face a higher risk of birth defects, according to new research from UTHealth Houston.

6 Oct 2023

What are the pharmacological properties of black goji berries?

The pharmacological effects of the components of Lycium ruthenicum Murray fruits.

29 Sep 2023

Weighing the risks and benefits of COVID-19 precautions in 2023

A new editorial paper was published in Oncotarget's Volume 14 on September 22, 2023, entitled, "Reassessing the risks and benefits of COVID-19 precautions in 2023."

28 Sep 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

MGI partners with National Cancer Centre Singapore to undergo comprehensive genomic profiling of Asian-Prevalent cancers

MGI Tech Singapore Pte, Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore ("NCCS") to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI's core DNBSEQ™ technology.

From MGI 18 Sep 2023

Kuano closes £1.8M seed funding round to validate quantum simulation platform for drug discovery

Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, today announced the close of its £1.8M seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other Angel investors.

From Kuano Ltd. 13 Sep 2023

New way to administer CAR-T-cell therapy could lead to fewer side effects

When Richard O'Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy easier on patients.

8 Sep 2023

Did COVID-19 mortality differ between patients with cancer and the general US population depending on which SARS-CoV-2 variant was dominant?

Researchers comparatively evaluated COVID-19 mortality among cancer patients during different periods of the SARS-CoV-2 outbreak.

4 Sep 2023

Universal approach could potentially expand CAR T cell therapy to all blood cancers

A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer.

31 Aug 2023

A comprehensive online resource allows for the exploration of interactions between mutational signatures and topographical features across human cancer

An online resource for studying the relationship between mutational signatures and topographical characteristics across human cancer.

28 Aug 2023

Scientists create new test to identify people at risk of developing myeloid leukemias

Scientists have created a new test for identifying people at risk of developing acute myeloid leukaemia and related cancers, years before they do.

24 Aug 2023

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

22 Aug 2023

The standard of care and recent advancements in the control of skin inflammation

Researchers discuss current therapeutic interventions for atopic dermatitis in children and adolescents.

21 Aug 2023

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Researchers examined the association between moderate alcohol intake and specific cancer risks.

21 Aug 2023

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Scientists have developed a lymph node-targeted multi-epitope subunit vaccine that induces strong humoral and cellular immune responses against EBV in mice.

14 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

CDK9 inhibitors: A promising new treatment for hematological malignancies

A new research perspective was published in Oncotarget's Volume 14 on August 7, 2023, entitled, "CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies."

9 Aug 2023

Researchers uncover genetic machinery responsible for EBV-induced B cell growth transformation

B cells or B lymphocytes are an important part of the body's immune system. When healthy B cells are infected with the Epstein-Barr virus (EBV), they undergo growth transformation, a process that immortalizes B cells, leading to their uncontrolled proliferation.

7 Aug 2023